Please ensure Javascript is enabled for purposes of website accessibility

Why Arcus Biosciences' Big Reveal Wasn't Very Exciting

By Cory Renauer - Jun 25, 2021 at 6:29AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

No news from Arcus Biosciences is bad news for the company and other industry heavyweights.

After the market closed on Wednesday, Arcus Biosciences (RCUS -7.75%) presented interim results from Arc-7 -- one of the most closely watched phase 2 clinical trials of the year. According to the company, patients who received the company's anti-Tigit antibody, domvanalimab, showed encouraging clinical activity.

Shares of Arcus rose on Thursday in response to the company's positive view of the study. But the lack of details provided was bad news for Arcus, its collaboration partner Gilead Sciences (GILD 0.65%), and some of the biopharmaceutical industry's biggest players. 

Scientist comparing two test tubes.

Image source: Getty Images.

Interim update

Over a year ago, Arcus Biosciences began Arc-7, a phase 2 clinical trial with 150 lung cancer patients randomized to receive zimberelimab, an experimental PD-1 blocker, as monotherapy or a combination of zimberelimab plus domvanalimab.

The Arc-7 study also randomized a third cohort to receive a triple combination that includes the company's experimental adenosine receptor blocker, etrumadenant.

While success for etrumadenant would be a positive for Arcus, the biotech industry was super eager to see response rate data for the domvanalimab plus zimberelimab cohort compared to the group that received zimberelimab monotherapy. That's because a slew of companies that market PD-1 blockers similar to zimberelimab have been trying to expand their utility by combining them with anti-Tigit antibodies.

Oncology's big white whale 

The most successful cancer therapies at the moment block the PD-1 pathway, which makes it harder for tumors to hide from the immune system. Sadly, a majority of patients don't respond to PD-1 blockade. Over half a dozen companies currently market approved PD-1 blockers, and they've wasted billions in recent years chasing drugs like domvanalimab that raise response rates.

In theory, blocking Tigit makes it harder for tumor cells to shut down the immune system when it attacks. In January, one of the industry's most successful cancer drug developers, Roche (RHHBY 0.46%), said it would invest heavily in an anti-Tigit antibody called tiragolumab after adding it to a PD-1 blocker appeared to nearly double lung cancer response rates in a phase 1 trial. 

Unfortunately, Roche followed up with results in May that showed it only appears to benefit patients with tumors that overexpress PD-L1. This is particularly disappointing because we know that this group already responds relatively well to PD-1 blockade with Tecentriq and similar drugs.

A person doing calculations with a pencil and calculator while looking at a laptop.

Image source: Getty Images.

Where's the data?

Management teams at biopharmaceutical companies large and small are always quick to tout any signs of success that can be gleaned from clinical trial data. On Wednesday, though, Arcus Biosciences declined to share response rate data from the Arc-7 study.

Arcus Biosciences' stock could skyrocket if we find out adding domvanalimab to PD-1 blockers improves patients' odds of long-term survival. Given the lack of success we've seen over the years from attempts to increase the utility of Tecentriq and drugs like it, the company's recent non-disclosure most likely means domvanalimab is a dud.

The stock made a slight gain on Thursday, thanks largely to the lack of safety issues for all three new drug candidates being tested in the Arc-7 trial. Arcus Biosciences still has a relatively modest $1.9 billion market cap, despite the recent run-up, because zimberelimab is the only cancer drug candidate in the company's late-stage pipeline with a reasonable chance to eventually earn approval from the FDA.

Gilead Sciences has taken a roughly 20% equity stake in Arcus, so we can count on Gilead to give Arcus Biosciences' cancer therapy candidates plenty of opportunities to prove themselves. Despite help from Gilead Sciences co-developing its new drug candidates, though, Arcus Biosciences still burned through $73 million in the first quarter. 

Each step toward earning approval for new drugs is more expensive than the one before it. The company finished March with a nice $885 million cash cushion, but this won't last very long if Gilead Sciences doesn't begin paying all rising research and development expenses for domvanalimab and the rest of Arcus Biosciences' cancer therapy candidates. For now, it's probably best to play wait and see with this risky stock.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arcus Biosciences, Inc. Stock Quote
Arcus Biosciences, Inc.
$25.23 (-7.75%) $-2.12
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.00 (0.65%) $0.40
Roche Holding AG Stock Quote
Roche Holding AG
$41.55 (0.46%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.